At the news
? NEUTRALIMPACT 6/10 PRESS-RELEASE filed Mar 9, 2026 at 07:05 ET
Relmada Therapeutics announced a $160 million PIPE financing through the sale of common stock and pre-funded warrants, with proceeds intended for R&D and general corporate purposes. The offering includes significant participation from major healthcare investors and is expected to close March 11, 2026, subject to customary conditions.
- Relmada raised $160 million in gross proceeds via a PIPE financing.
- The offering includes 29,474,569 shares of common stock at $4.75 per share and pre-funded warrants for 4,210,527 shares at $4.749 per warrant.
- Pre-funded warrants have an exercise price of $0.001 per share.
- Proceeds will fund working capital, R&D advancement, and general corporate purposes.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access